Covid19NCT04487873
COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic
An observational study of Covid19 and Bronchiectasis, run by Hacettepe University at 1 site in Turkey (Türkiye).
Trial summary
In the literature, there are no studies evaluating COVID-19 phobia, quality of life, health anxiety, physical activity level and quality of sleep in patients with bronchiectasis during COVID-19 pandemic. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Covid19, Bronchiectasis
- How many people
- 74 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 23 Jul 2020to 31 Jan 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Patients and healthy individuals between 18-60 years old, who are diagnosed with non-cystic fibrosis bronchiectasis, and whose local language is Turkish will be included in the study.
Who may be able to join
- Having been diagnosed with non-cystic fibrosis bronchiectasis
- No acute bronchiectasis exacerbation or infection in the past 2 weeks
- Volunteering to participate in the research
Who cannot join
- Having a cognitive problem
- Not being literate
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Hacettepe University, Faculty of Physical Therapy and Rehabilitation
Ankara
About this study
Official title: COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic
In the literature, there are no studies evaluating COVID-19 phobia, quality of life, health anxiety, physical activity level and quality of sleep in patients with bronchiectasis during COVID-19 pandemic. The investigators will evaluate these parameters in patients with bronchiectasis and compare the findings of healthy individuals during COVID-19 pandemic
- Conditions
- Covid19, Bronchiectasis
- Keywords
- phobia, quality of life, health anxiety
- Medical subject headings
- COVID-19, Bronchiectasis, Phobic Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Bronchiectasis | Having been diagnosed with non-cystic fibrosis bronchiectasis | |
| Healthy individuals | Healthy individuals without chronic disease |
What is being measured
The primary outcome is the main question the study is designed to answer.
COVID-19 Phobia
COVID-19 phobia was evaluated with COVID-19 Phobia Scale (C19P-S) and total score ranges from 20-100. Lower scores mean better outcome.
Measured: 5 minutes
Qol
Quality of life was evaluated with Nottingham Health Profile
Measured: 10 minutes
Secondary outcomes (3)
Health anxiety
Health anxiety was evaluated with Health Anxiety Inventory
Measured: 10 minutes
Physical activity
Physical activity level was evaluated with International Physical Activity Questionnaire - Short Form (IPAQ-SF)
Measured: 5 minutes
Quality of sleep
Quality of sleep was evaluated with Pittsburgh Sleep Quality Index
Measured: 10 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jul 2020
- Study start23 Jul 2020
- Primary completion18 Dec 2020
- Study completion31 Jan 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid19Studies of the same condition, open and under way.
- More trials run by Hacettepe UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 74 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hacettepe University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Merve Firat, Hacettepe University
- Investigators
- Merve Firat, MSc, Principal investigator, Hacettepe UniversityNaciye Vardar-Yagli, PhD, Study director, Hacettepe UniversityDeniz İnal-İnce, Professor, Study chair, Hacettepe UniversityMelda Saglam, PhD, Study chair, Hacettepe UniversityEbru Calik-Kütükcü, PhD, Study chair, Hacettepe UniversityAslıhan Cakmak, MSc, Study chair, Hacettepe University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04487873
- Sponsor's protocol ID
- GO 20/602
- Status last verified
- Dec 2020
- First submitted
- 23 Jul 2020
- Last updated
- 13 May 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic
- ClinicalTrials.gov ID
- NCT04487873
- Acronym / sponsor ID
- GO 20/602
- Conditions
- Covid19, Bronchiectasis
- Keywords
- phobia, quality of life, health anxiety
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 74 participants (actual)
- Lead sponsor
- Hacettepe UniversityUniversity, hospital or other
- Study start
- 23 Jul 2020 (actual)
- Primary completion
- 18 Dec 2020 (actual)
- Study completion
- 31 Jan 2021 (actual)
- First posted
- 27 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In the literature, there are no studies evaluating COVID-19 phobia, quality of life, health anxiety, physical activity level and quality of sleep in patients with bronchiectasis during COVID-19 pandemic. The investigators will evaluate these parameters in patients with bronchiectasis and compare the findings of healthy individuals during COVID-19 pandemic
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bronchiectasis | – | –Having been diagnosed with non-cystic fibrosis bronchiectasis |
| Healthy individuals | – | –Healthy individuals without chronic disease |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Patients and healthy individuals between 18-60 years old, who are diagnosed with non-cystic fibrosis bronchiectasis, and whose local language is Turkish will be included in the study.
Key inclusion criteria (3 listed)
- Having been diagnosed with non-cystic fibrosis bronchiectasis
- No acute bronchiectasis exacerbation or infection in the past 2 weeks
- Volunteering to participate in the research
Key exclusion criteria (2 listed)
- Having a cognitive problem
- Not being literate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
COVID-19 Phobia
Time frame: 5 minutes
COVID-19 phobia was evaluated with COVID-19 Phobia Scale (C19P-S) and total score ranges from 20-100. Lower scores mean better outcome.
Qol
Time frame: 10 minutes
Quality of life was evaluated with Nottingham Health Profile
3 secondary outcomes
Health anxiety
Time frame: 10 minutes
Physical activity
Time frame: 5 minutes
Quality of sleep
Time frame: 10 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2021.
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Merve Firat, MSc principal investigator
Hacettepe University
Naciye Vardar-Yagli, PhD study director
Hacettepe University
Deniz İnal-İnce, Professor study chair
Hacettepe University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19 and Bronchiectasis, run by Hacettepe University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
COVID-19 Phobia (time frame: 5 minutes). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2021.